Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanwal Raghav

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 15, 2022
Quality-of-life concerns in patients with metastatic colorectal cancerKanwal Raghav
The New England Journal of Medicine|May 28, 2025
Cancer of Unknown Primary SiteKanwal Raghav
The New England Journal of Medicine|August 13, 2025
Cancer of Unknown Primary Site. ReplyKanwal Raghav
Future Oncology (London, England)|January 5, 2026
Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 studyKanwal Raghav
The Lancet. Oncology|October 31, 2024
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?Ryan Huey, Kanwal Raghav
JAMA Oncology|August 16, 2019
The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal CancerKanwal Raghav, John H Strickler
Nature Reviews. Clinical Oncology|July 31, 2013
Small bowel adenocarcinomas--existing evidence and evolving paradigmsKanwal Raghav, Michael J Overman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2023
Reply to Y. Yu et alKanwal Raghav, Scott Kopetz, Ying Yuan
Surgical Oncology Clinics of North America|September 20, 2017
An Update on Randomized Clinical Trials in Metastatic Colorectal CarcinomaNaruhiko Ikoma, Kanwal Raghav, George Chang
Oncology (Williston Park, N.Y.)|October 19, 2022
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, Kanwal Raghav, Scott Kopetz
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Clinical Advances in Hematology & Oncology : H&O|March 15, 2022
Quality-of-life concerns in patients with metastatic colorectal cancerKanwal Raghav
The New England Journal of Medicine|May 28, 2025
Cancer of Unknown Primary SiteKanwal Raghav
The New England Journal of Medicine|August 13, 2025
Cancer of Unknown Primary Site. ReplyKanwal Raghav
Future Oncology (London, England)|January 5, 2026
Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 studyKanwal Raghav
The Lancet. Oncology|October 31, 2024
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?Ryan Huey, Kanwal Raghav
JAMA Oncology|August 16, 2019
The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal CancerKanwal Raghav, John H Strickler
Nature Reviews. Clinical Oncology|July 31, 2013
Small bowel adenocarcinomas--existing evidence and evolving paradigmsKanwal Raghav, Michael J Overman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2023
Reply to Y. Yu et alKanwal Raghav, Scott Kopetz, Ying Yuan
Surgical Oncology Clinics of North America|September 20, 2017
An Update on Randomized Clinical Trials in Metastatic Colorectal CarcinomaNaruhiko Ikoma, Kanwal Raghav, George Chang
Oncology (Williston Park, N.Y.)|October 19, 2022
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, Kanwal Raghav, Scott Kopetz
Pageof 11